NY‐ESO‐1 expression is tightly linked to TMPRSS2–ERG fusion in prostate cancer

NY‐ESO‐1 has been suggested as therapeutic cancer vaccine in prostate cancer. This study was undertaken to explore the relationship of NY‐ESO‐1 with tumor phenotype, biochemical recurrence, and molecular subgroups in hormone‐naive prostate cancers.

[1]  J. Korbel,et al.  Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2:ERG fusions , 2013, Modern Pathology.

[2]  G. Sauter,et al.  Cysteine-rich secretory protein 3 overexpression is linked to a subset of PTEN-deleted ERG fusion-positive prostate cancers with early biochemical recurrence , 2013, Modern Pathology.

[3]  G. Sauter,et al.  CHD1 is a 5q21 tumor suppressor required for ERG rearrangement in prostate cancer. , 2013, Cancer research.

[4]  T. H. van der Kwast,et al.  Altered DNA Methylation Landscapes of Polycomb-Repressed Loci Are Associated with Prostate Cancer Progression and ERG Oncogene Expression in Prostate Cancer , 2013, Clinical Cancer Research.

[5]  H. Lehrach,et al.  ERG Induces Epigenetic Activation of Tudor Domain-Containing Protein 1 (TDRD1) in ERG Rearrangement-Positive Prostate Cancer , 2013, PloS one.

[6]  C. Plass,et al.  Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. , 2012, The American journal of pathology.

[7]  S. Edge,et al.  NY-ESO-1 Cancer Testis Antigen Demonstrates High Immunogenicity in Triple Negative Breast Cancer , 2012, PloS one.

[8]  Bruce J Trock,et al.  Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades. , 2012, European urology.

[9]  Y. Doki,et al.  Heteroclitic serological response in esophageal and prostate cancer patients after NY‐ESO‐1 protein vaccination , 2012, International journal of cancer.

[10]  Tim Beißbarth,et al.  TMPRSS2-ERG -specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-β signaling , 2011, BMC Cancer.

[11]  M. Chebil,et al.  NY-ESO-1 expression and immunogenicity in prostate cancer patients. , 2011, La Tunisie medicale.

[12]  H. Schlüter,et al.  ERG Status Is Unrelated to PSA Recurrence in Radically Operated Prostate Cancer in the Absence of Antihormonal Therapy , 2011, Clinical Cancer Research.

[13]  D. Jäger,et al.  Protein expression of cancer testis antigens predicts tumor recurrence and treatment response to imatinib in gastrointestinal stromal tumors , 2011, International journal of cancer.

[14]  A. Haese*,et al.  High level PSMA expression is associated with early psa recurrence in surgically treated prostate cancer , 2011, The Prostate.

[15]  R. Scolyer,et al.  Cancer-testis antigen expression in primary cutaneous melanoma has independent prognostic value comparable to that of Breslow thickness, ulceration and mitotic rate. , 2011, European journal of cancer.

[16]  J. Karbach,et al.  Efficient In vivo Priming by Vaccination with Recombinant NY-ESO-1 Protein and CpG in Antigen Naïve Prostate Cancer Patients , 2010, Clinical Cancer Research.

[17]  Eric S. Lander,et al.  The genomic complexity of primary human prostate cancer , 2010, Nature.

[18]  O. Kallioniemi,et al.  FZD4 as a mediator of ERG oncogene-induced WNT signaling and epithelial-to-mesenchymal transition in human prostate cancer cells. , 2010, Cancer research.

[19]  C. Sander,et al.  Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.

[20]  E. Fischer,et al.  Yeast-based identification of prostate tumor antigens provides an effective vaccine platform. , 2010, Anticancer research.

[21]  G. Sauter,et al.  Chromosome 8p Deletions and 8q Gains are Associated with Tumor Progression and Poor Prognosis in Prostate Cancer , 2009, Clinical Cancer Research.

[22]  Steven S. Chang,et al.  Integrative Discovery of Epigenetically Derepressed Cancer Testis Antigens in NSCLC , 2009, PloS one.

[23]  Yao-Tseng Chen,et al.  Cancer/testis (CT) antigens: Potential targets for immunotherapy , 2009, Cancer science.

[24]  M. Rubin,et al.  INTEGRATION OF ERG GENE MAPPING AND GENE‐EXPRESSION PROFILING IDENTIFIES DISTINCT CATEGORIES OF HUMAN PROSTATE CANCER , 2009, BJU international.

[25]  A. Haese*,et al.  Clinical significance of p53 alterations in surgically treated prostate cancers , 2008, Modern Pathology.

[26]  J. Brooks,et al.  Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. , 2007, Cancer research.

[27]  S. Vogel,et al.  Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming , 2007, Proceedings of the National Academy of Sciences.

[28]  Y. Doki,et al.  Antibody response against NY‐ESO‐1 in CHP‐NY‐ESO‐1 vaccinated patients , 2007, International journal of cancer.

[29]  B. Brodin,et al.  Concise Review: Cancer/Testis Antigens, Stem Cells, and Cancer , 2007, Stem cells.

[30]  D. Jäger,et al.  Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients , 2006, Proceedings of the National Academy of Sciences.

[31]  J. Tchinda,et al.  Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. , 2006, Science.

[32]  Lloyd J. Old,et al.  Cancer/testis antigens, gametogenesis and cancer , 2005, Nature Reviews Cancer.

[33]  Y. Doki,et al.  NY-ESO-1 Expression and Immunogenicity in Esophageal Cancer , 2004, Clinical Cancer Research.

[34]  P. Diener,et al.  Adaptive Immuntherapie des fortgeschrittenen Prostatakarzinoms - Cancer Testis Antigene (CTA) als mögliche Zielantigene , 2004 .

[35]  Mark Shackleton,et al.  Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[36]  E. Smeland,et al.  NY‐ESO‐1 protein expression and humoral immune responses in prostate cancer , 2004, The Prostate.

[37]  K. Hatakeyama,et al.  NY-ESO-1 expression and its serum immunoreactivity in esophageal cancer , 2004, Cancer Chemotherapy and Pharmacology.

[38]  M. Monden,et al.  NY-ESO-1 Expression and Immunogenicity in Malignant and Benign Breast Tumors , 2004, Cancer Research.

[39]  Danila Valmori,et al.  Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine. , 2003, Cancer immunity.

[40]  Yao-Tseng Chen,et al.  NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. , 2003, Cancer research.

[41]  Yao-Tseng Chen,et al.  CD8+ T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[42]  M. Ladanyi,et al.  Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen ny‐eso‐1 but not mage‐a1 or ct7 , 2001, International journal of cancer.

[43]  D. Jäger,et al.  Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[44]  Lloyd J. Old,et al.  A Survey of the Humoral Immune Response of Cancer Patients to a Panel of Human Tumor Antigens , 1998, The Journal of experimental medicine.

[45]  Yao-Tseng Chen,et al.  A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[46]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[47]  Ronald Simon,et al.  Recipient block TMA technique. , 2010, Methods in molecular biology.

[48]  Y. Doki,et al.  T cell immunomonitoring and tumor responses in patients immunized with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein. , 2007, Cancer immunity.

[49]  A. Simpson,et al.  Physical interaction of two cancer-testis antigens, MAGE-C1 (CT7) and NY-ESO-1 (CT6). , 2006, Cancer immunity.

[50]  M. Jefford,et al.  The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand. , 2004, Cancer immunity.

[51]  D. Engeler,et al.  [Adaptive immunotherapy of the advanced prostate cancer - cancer testis antigen (CTA) as possible target antigens]. , 2004, Aktuelle Urologie.

[52]  L. Old.  Cancer vaccines 2003: opening address. , 2003, Cancer immunity.

[53]  Zihai Li,et al.  Cell surface expression of heat shock protein gp96 enhances cross-presentation of cellular antigens and the generation of tumor-specific T cell memory. , 2003, Cancer immunity.

[54]  Yao-Tseng Chen,et al.  NY-ESO-1 mRNA expression and immunogenicity in advanced prostate cancer. , 2003, Cancer immunity.

[55]  M. Graefen,et al.  Tumour grade, proliferation, apoptosis, microvessel density, p53, and bcl-2 in prostate cancers: differences between tumours located in the transition zone and in the peripheral zone. , 2002, European urology.

[56]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.